ALGN stock trades on product momentum and margin pressure

Align Technology Inc. (US01741R1023) is the company behind ALGN stock, and the most recent published figures show why the share remains sensitive to report-day details: revenue was $1.015 billion in fiscal 2025, up 1.8% from $997.4 million in fiscal 2024, while GAAP net income was $160.6 million versus $295.6 million a year earlier. The company also said it ended fiscal 2025 with $979.3 million in cash and cash equivalents, giving the balance sheet a visible cushion as the business leans on the Invisalign franchise.

Revenue up 1.8%

For investors, the key number is the pace of sales rather than the brand name alone. Align reported fiscal 2025 revenue of $1.015 billion, a 1.8% increase from fiscal 2024, but GAAP net income fell to $160.6 million from $295.6 million, a drop of $135.0 million year over year.

The margin picture moved in the wrong direction on the same comparison. Lower profitability matters because the company is still working through demand and mix shifts in a category that depends on orthodontic adoption and recurring case volumes.

Cash and earnings gap

Align Technology said fiscal 2025 cash and cash equivalents stood at $979.3 million, while diluted earnings per share were $2.14 on a GAAP basis and $3.35 on a non-GAAP basis for the year. That spread between GAAP and adjusted earnings is one of the clearest signals in the report set: operating performance and accounting results are not telling the same story.

The comparison is also meaningful against the prior year because the company’s GAAP earnings base was materially higher in fiscal 2024. A year-on-year decline from $295.6 million to $160.6 million in net income points to a tougher profit conversion even with a revenue increase.

Invisalign stays central

Invisalign remains the core product line that shapes the whole investment case. Align uses the system as its main commercial engine, so quarterly and annual movements in case volume, regional adoption, and doctor utilization feed directly into the stock’s valuation debate.

The product mix matters because investors typically read the line item flow before they read the brand story. In a year with $1.015 billion in revenue, the question is whether Invisalign demand can support more stable earnings and a stronger operating margin in the next reporting cycle.

Fiscal 2025 in focus

The fiscal 2025 report gives a clean reference point for the next move in ALGN stock. Revenue at $1.015 billion, GAAP net income at $160.6 million, and cash of $979.3 million are the three figures that frame the current setup, and the revenue-to-profit gap is the most important comparison inside that set.

That gap is what the market usually prices first when a healthcare technology company depends on both unit growth and margin recovery. If the next update shows better earnings conversion against the same revenue base, the stock has a more credible fundamental bridge than if sales move alone.

Invisalign platform

Invisalign is still the business line that defines Align Technology’s public market profile. It is the product most closely tied to case starts, utilization trends, and the company’s ability to turn sales growth into more consistent earnings.

Stock level and venue

ALGN stock trades on the Nasdaq under the symbol NASDAQ: ALGN. As a market reference, the latest report context centers on fiscal 2025 revenue of $1.015 billion and net income of $160.6 million, with the balance sheet showing $979.3 million in cash and cash equivalents.